Kupando Secures Additional €10 Million in Series A Financing to Advance Novel Immuno-Oncology and Infectious Diseases Programs

Kupando raised an additional €10 million in Series A financing, bringing the total Series A funding to €23 million. Investment again led by Remiges Ventures, co-led by LifeCare Partners, with participation from all existing investors and new investor Carma Fund. Proceeds will be used to fund the Phase 1b clinical study of KUP101 in advanced solid tumors and to accelerate preclinical programs in infectious diseases. KUP101 is a differentiated dual TLR 4 and 7 agonist, harnessing innate immune stimulation and trained innate immunity. SCHÖNEFELD, Germany, March 18, 2026 / Biotech Newswire / -- Kupando , a pioneering biopharmaceutical company developing a TLR 4/7 agonist ...